HC Wainwright set a $48.00 price objective on Uniqure (NASDAQ:QURE) in a report released on Thursday. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other research analysts also recently commented on the company. Zacks Investment Research raised Uniqure from a hold rating to a buy rating and set a $33.00 target price for the company in a research note on Wednesday, October 10th. BidaskClub downgraded Uniqure from a strong-buy rating to a buy rating in a research note on Friday, September 28th. Chardan Capital boosted their target price on Uniqure from $50.00 to $70.00 and gave the stock a buy rating in a research note on Wednesday, November 7th. Cantor Fitzgerald set a $58.00 target price on Uniqure and gave the stock a buy rating in a research note on Wednesday, October 3rd. Finally, Janney Montgomery Scott reissued a buy rating on shares of Uniqure in a research note on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and an average target price of $54.33.

QURE opened at $31.84 on Thursday. Uniqure has a twelve month low of $14.27 and a twelve month high of $43.23. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.56 and a quick ratio of 7.56. The stock has a market cap of $1.19 billion, a P/E ratio of -10.83 and a beta of 0.78.

Uniqure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.03. The firm had revenue of $3.15 million during the quarter, compared to the consensus estimate of $3.37 million. Uniqure had a negative return on equity of 58.49% and a negative net margin of 725.04%. As a group, analysts anticipate that Uniqure will post -2.53 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its stake in shares of Uniqure by 12.8% in the third quarter. Bank of New York Mellon Corp now owns 18,747 shares of the biotechnology company’s stock valued at $682,000 after buying an additional 2,129 shares during the period. RTW Investments LP increased its stake in shares of Uniqure by 0.7% in the second quarter. RTW Investments LP now owns 409,370 shares of the biotechnology company’s stock valued at $15,474,000 after buying an additional 2,703 shares during the period. Wells Fargo & Company MN increased its stake in shares of Uniqure by 24.2% in the third quarter. Wells Fargo & Company MN now owns 17,829 shares of the biotechnology company’s stock valued at $649,000 after buying an additional 3,472 shares during the period. Allianz Asset Management GmbH increased its stake in shares of Uniqure by 9.4% in the third quarter. Allianz Asset Management GmbH now owns 54,332 shares of the biotechnology company’s stock valued at $1,977,000 after buying an additional 4,679 shares during the period. Finally, Credit Suisse AG increased its stake in shares of Uniqure by 20.8% in the third quarter. Credit Suisse AG now owns 28,271 shares of the biotechnology company’s stock valued at $1,028,000 after buying an additional 4,859 shares during the period. 59.10% of the stock is owned by institutional investors.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Further Reading: Market Capitalization and Individual Investors

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.